To investigate the expression patterns of Nectin‐4, the target molecule of the antibody‐drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC). Here, NECTIN4 is linked to bladder transitional cell carcinoma.